OCULAR THERAPEUTIX, INC Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
OCULAR THERAPEUTIX, INC (OCUL) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 5.41 million shares for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-05.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2021-05-05
- OCULAR THERAPEUTIX, INC incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2021-03-31 was 5.41M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month |
|---|---|
| 2021-03-31 | 5.41M shares 10-Q · filed 2021-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |